Ladenburg Thalmann & Co. Thinks Armata Pharmaceuticals Inc’s Stock is Going to Recover

By Austin Angelo

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. reiterated a Buy rating on Armata Pharmaceuticals Inc (ARMPResearch Report), with a price target of $9. The company’s shares opened today at $3.40, close to its 52-week low of $2.15.

According to TipRanks.com, Higgins ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -7.8% and a 29.9% success rate. Higgins covers the Healthcare sector, focusing on stocks such as Rhythm Pharmaceuticals Inc, Achieve Life Sciences Inc, and Melinta Therapeutics Inc.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Armata Pharmaceuticals Inc with a $8 average price target.

See today’s analyst top recommended stocks >>

Based on Armata Pharmaceuticals Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $3.62 million. In comparison, last year the company had a GAAP net loss of $3.05 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.